160 related articles for article (PubMed ID: 38878446)
1. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.
Verschoor N; Bos MK; Oomen-de Hoop E; Martens JWM; Sleijfer S; Jager A; Beije N
Eur J Cancer; 2024 Jun; 207():114159. PubMed ID: 38878446
[TBL] [Abstract][Full Text] [Related]
2. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
3. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
4. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
[TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.
Chakrabarti S; Xie H; Urrutia R; Mahipal A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003583
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
Peng Y; Mei W; Ma K; Zeng C
Front Oncol; 2021; 11():763790. PubMed ID: 34868984
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
Solar Vasconcelos JP; Boutin M; Loree JM
Ther Adv Med Oncol; 2022; 14():17588359221143975. PubMed ID: 36570410
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
11. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
13. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
[TBL] [Abstract][Full Text] [Related]
14. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC).
Masfarré L; Vidal J; Fernández-Rodríguez C; Montagut C
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201274
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
16. ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study.
Callesen LB; Hansen TF; Andersen RF; Pallisgaard N; Kramer S; Schlander S; Rafaelsen SR; Boysen AK; Jensen LH; Jakobsen A; Spindler KG
Acta Oncol; 2023 Dec; 62(12):1742-1748. PubMed ID: 37738268
[TBL] [Abstract][Full Text] [Related]
17. Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer.
Gottschalk Z; Cohen SA
Curr Oncol Rep; 2024 Jun; ():. PubMed ID: 38842605
[TBL] [Abstract][Full Text] [Related]
18. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
Larribère L; Martens UM
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830853
[TBL] [Abstract][Full Text] [Related]
19. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
20. ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm.
Naidoo M; Gibbs P; Tie J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]